Abstract

IntroductionJuvenile dermatomyositis (JDM) can be classified into clinical serological subgroups by distinct myositis-specific antibodies (MSAs). It is incompletely understood whether different MSAs are associated with distinct pathological characteristics, clinical disease activities, or response to treatment.MethodsWe retrospectively reviewed clinicopathological data from consecutive JDM patients followed in the pediatric rheumatology clinic at a single center between October 2016 and November 2018. Demographics, clinical data, and laboratory data were collected and analyzed. Detailed muscle biopsy evaluation of four domains (inflammation, myofiber, vessels, and connective tissue) was performed, followed by statistical analysis.ResultsOf 43 subjects included in the study, 26 (60.5%) had a detectable MSA. The most common MSAs were anti-NXP-2 (13, 30.2%), anti-Mi-2 (7, 16.3%), and anti-MDA-5 (5, 11.6%). High titer anti-Mi-2 positively correlated with serum CK > 10,000 at initial visit (r = 0.96, p = 0.002). Muscle biopsied from subjects with high titer anti-Mi-2 had prominent perifascicular myofiber necrosis and perimysial connective tissue damage that resembled perifascicular necrotizing myopathy, but very little capillary C5b-9 deposition. Conversely, there was no positive correlation between the levels of the anti-NXP-2 titer and serum CK (r = − 0.21, p = 0.49). Muscle biopsies from patients with anti-NXP-2 showed prominent capillary C5b-9 deposition; but limited myofiber necrosis. Only one patient had anti-TIF1γ autoantibody, whose muscle pathology was similar as those with anti-NXP2. All patients with anti-MDA-5 had normal CK and near normal muscle histology.ConclusionsMuscle biopsy from JDM patients had MSA specific tissue injury patterns. These findings may help improve muscle biopsy diagnosis accuracy and inform personalized treatment of JDM.

Highlights

  • Juvenile dermatomyositis (JDM) can be classified into clinical serological subgroups by distinct myositis-specific antibodies (MSAs)

  • Juvenile dermatomyositis (JDM) is the most common type of juvenile idiopathic inflammatory myopathy (IIM), and is characterized clinically by proximal muscle weakness, elevated muscle enzymes, and skin rashes in patients with onset before the age of 18

  • We found alkaline phosphatase enzyme histochemical stain and C5b-9 immunostain helpful in differentiating the pathology of JDM MSA groups

Read more

Summary

Introduction

Juvenile dermatomyositis (JDM) can be classified into clinical serological subgroups by distinct myositis-specific antibodies (MSAs). It is incompletely understood whether different MSAs are associated with distinct pathological characteristics, clinical disease activities, or response to treatment. Cases of myositis associated with anti-SRP and anti-HMGCR autoantibodies, in contrast, Nguyen et al Acta Neuropathologica Communications (2020) 8:125 are classified as necrotizing autoimmune myopathy; and cases of myositis associated with Jo-1, PL-7 and PL-12 autoantibodies are classified as antisynthetase syndrome associated myositis [7, 8] Patients in these latter two groups are no longer classified as dermatomyositis even if they have typical dermatomyositis type rashes per the most recent updates from the European Neuromuscular Center (ENMC) international workshop [7]. A unifying feature in all dermatomyositis subtypes is upregulation of type I interferon (IFN) signature genes, such as myxovirus resistant protein 1 (MxA) [9]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call